LY3872386 / Eli Lilly - LARVOL DELTA

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis (clinicaltrials.gov) - P1 | N=18 | Terminated | Sponsor: Eli Lilly and Company | N=179 ➔ 18 | Trial completion date: Jan 2026 ➔ Apr 2024 | Recruiting ➔ Terminated | Trial primary completion date: Jan 2026 ➔ Apr 2024; Based on emerging nonclinical data, the study was terminated.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis (clinicaltrials.gov) - P1 | N=179 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: May 2025 ➔ Jan 2026 | Trial primary completion date: May 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis (clinicaltrials.gov) - P1 | N=179 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology